003520 — Yungjin Pharm Co Income Statement
0.000.00%
- KR₩329bn
- KR₩395bn
- KR₩254bn
Annual income statement for Yungjin Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 196,067 | 218,381 | 234,902 | 252,040 | 254,256 |
| Cost of Revenue | |||||
| Gross Profit | 57,936 | 64,734 | 72,121 | 80,349 | 77,155 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 209,944 | 239,858 | 235,780 | 245,199 | 250,560 |
| Operating Profit | -13,877 | -21,477 | -877 | 6,841 | 3,696 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -14,144 | -22,813 | -3,918 | 2,887 | -212 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -11,582 | -21,961 | -3,876 | 1,233 | -228 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -11,582 | -21,961 | -3,876 | 1,233 | -228 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -11,582 | -21,961 | -3,876 | 1,233 | -228 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -62.8 | -68.1 | -5.88 | 11.3 | -2.66 |
| Dividends per Share |